We report a new case of Primary hepatic neuroendocrine carcinoma admitted in our hospital and revealed in 53 years man by epigastric pain and flush syndrome. A liver biopsy with immunohistochemical study confirmed the original location of a neuroendocrine carcinoma. After 12 cures of Chemotherapy and a follow up of 12 months, the patient is still in complete remission.
Introduction
Endocrine tumors are characterized by a common phenotype general markers (i.e., neuron-specific enolase, chromogranin, synaptophysin) and hormonal secretion products. Primitive hepatic localization is very rare, representing less than 0.3% of all endocrine tumors of the digestive system with a female predominance; the sex ratio is 1.6 / 1, with an average age of 51 [1, 2] .
Patient and observation
We report a case of primary hepatic neuroendocrine carcinoma 
Discussion
Primary hepatic neuroendocrine carcinoma is rare [1, 2] , clincal symptoms are not specific, and imaging is fundamental to guide diagnosis. Serum 5-HT or hydroxyindoleacetic acid (5-HIAA) 24 h urine levels may be effective markers with sensitivity of 73% and a specificity of more than 90%. Serum (CGA) is a sensitive marker in the diagnosis with a sensitivity of 87-100% and a specificity of 92%, but diagnosis confirmation is the histoligical examination after biopsy or surgery [3] .
It is difficult to differentiate PHNEC from other solid tumors, especially hepatocellular carcinoma or hepatic metastasis of other tumor; therefore, postoperative pathologic examination is the main method for a final diagnosis [1, 4] . Treatment includes several methods, surgery, systemic chemotherapy and transcatheter arterial chemoembo-lization [5, 6] . Prognosis depends on the initial stage of the disease. Research indicated that the recurrence rate at 5 years was 18% and the survival rate at 5 years was 74% -78% [7] .
Conclusion
Primary hepatic neuroendocrine carcinoma remains a rare diagnosis, requiring careful biological, endoscopic, radiological and histological examinations to eliminate the secondary localization of extrahepatic tumor. 
